Delve Bio, a pioneer in metagenomic sequencing, today announced the commercial launch of Delve Detect, its groundbreaking metagenomic test for infectious diseases. Built on the platform developed at the University of California San Francisco (UCSF), Delve Detect offers genomic testing of cerebrospinal fluid (CSF) for more than 68,000 pathogens, with a 48-hour turnaround time and metagenomics experts readily available to discuss results.
“Building on years of clinical experience, Delve Bio’s robust approach to metagenomic sequencing will transform testing and treatment for infectious diseases by delivering the most conclusive, unbiased and actionable diagnosis available today,” said Joe DeRisi, Ph.D., Delve Bio co-founder, Professor of Biochemistry and Biophysics at UCSF, and president of the Chan Zuckerberg Biohub San Francisco. “Delve Detect offers exactly that combination of technology and support to ensure laboratories and physicians can make the best treatment decisions for patients facing serious central nervous system infections.”
Delve was founded by Charles Chiu, Joe DeRisi, and Michael Wilson, all UCSF researchers. Congratulation!